Unum Therapeutics Inc. | 200 Cambridge Park Drive Suite 3100 | Cambridge, MA 02140  USA

Tel. +1.617.945.5576 | Email: info@unumrx.com

  • LinkedIn - White Circle
  • Twitter - White Circle

© Copyright 2014-2019 Unum Therapeutics

Unum’s leadership possesses biotech and large pharma drug development experience and deep scientific expertise in cancer immunotherapy.



Charles "Chuck" Wilson, PhD

Chief Executive Officer



Seth Ettenberg, PhD

Chief Scientific Officer



Geoffrey Hodge

Chief Technical Officer



Michael Vasconcelles, MD

Chief Medical Officer


Charles "Chuck" Wilson
Chief Executive Officer


Chuck leads the company. Before founding Unum Therapeutics, Chuck led partnering for Novartis research, and was responsible for all efforts in drug discovery up through Phase II clinical development. He brings deal experience in biotech and academic collaborations, product in-licensing, spin-outs, and strategic equity investing in early stage companies. Prior to Novartis, Chuck held both scientific and business management roles in biotechnology. Chuck received his PhD from the University of California, San Francisco, and completed his post-doctoral training at Harvard University / Massachusetts General Hospital. In addition to his responsibilities at Unum, Chuck serves as a director on the board of Gigagen, Inc. and as vice chair of the Massachusetts Biotechnology Council ('MassBIO').